Dyne Therapeutics, Inc. Interest Expense, Other
Dyne Therapeutics, Inc. (DYN) reported Interest Expense, Other of $4.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseOther · last filed 2026-07-29
- Dyne Therapeutics, Inc. interest expense, other for the quarter ending 2026-06-30 was $4.59M, a 4788.30% increase year-over-year.
- Dyne Therapeutics, Inc. interest expense, other for the quarter ending 2026-03-31 was $4.20M.
- Dyne Therapeutics, Inc. interest expense, other for the quarter ending 2025-12-31 was $3.19M.
- Dyne Therapeutics, Inc. interest expense, other for the quarter ending 2025-09-30 was $2.90M.
- Dyne Therapeutics, Inc. interest expense, other for fiscal 2025 was $6.19M.
- Dyne Therapeutics, Inc. interest expense, other for fiscal 2024 was $0.00.
- Dyne Therapeutics, Inc. interest expense, other for fiscal 2023 was $0.00.
- Dyne Therapeutics, Inc. interest expense, other for fiscal 2020 was $396.00K.
| Period end | Interest Expense, Other 3 month | Interest Expense, Other 6 month | Interest Expense, Other 9 month | Interest Expense, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.59M 10-Q · filed 2026-07-29 | $8.80M 10-Q · filed 2026-07-29 | $11.99M derived: sum of 3 quarters · filed 2026-07-29 | $14.89M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $4.20M 10-Q · filed 2026-05-11 | $7.40M derived: sum of 2 quarters · filed 2026-05-11 | $10.30M derived: sum of 3 quarters · filed 2026-05-11 | $10.39M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.10M derived: sum of 2 quarters · filed 2026-03-02 | $6.19M derived: sum of 3 quarters · filed 2026-07-29 | $6.19M 10-K · filed 2026-03-02 |
| 2025-09-30 | $2.90M 10-Q · filed 2025-11-05 | $3.00M derived: sum of 2 quarters · filed 2026-07-29 | $3.00M 10-Q · filed 2025-11-05 | $3.00M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $94.00K 10-Q · filed 2026-07-29 | $94.00K 10-Q · filed 2026-07-29 | $94.00K derived: sum of 3 quarters · filed 2026-07-29 | $94.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | $0.00 derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-07-28 | $0.00 10-Q · filed 2025-07-28 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2020-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $211.00K derived: sum of 2 quarters · filed 2022-03-10 | $338.00K derived: sum of 3 quarters · filed 2022-03-10 | $396.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $130.00K 10-Q · filed 2021-11-04 | $257.00K derived: sum of 2 quarters · filed 2021-11-04 | $315.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $127.00K 10-Q · filed 2021-08-05 | $184.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $57.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |